Evidence map›Paper›PMID 36932369›Full record

ArticleBMC public health2023

Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.

Angela R Bazzi, Michelle Bordeu, Katrina Baumgartner, Darien M Sproesser, Christopher M Bositis, Douglas S Krakower, Matthew J Mimiaga, Katie B Biello

Registry-linked trialOpen access · goldFull text readClinical Trial Protocol
In one paragraph

Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04430257 (Efficacy of a Community-based PrEP Uptake Intervention for People Who Inject Drugs), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04430257 narecruitingnot on this map

Efficacy of a Community-based PrEP Uptake Intervention for People Who Inject Drugs (PWID) in the US Northeast

TypeinterventionalSponsorBrown UniversityRan2021 to 2026Enrolled200ConditionsSubstance Dependence, HIV (Human Immunodeficiency Virus)ArmsHIV and PrEP education, Motivational interviewing, Problem-solving and planning, Patient navigation, PrEP information
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. The Health Toll of Encampment Sweeps: A Descriptive Analysis of People Who Use Drugs in Massachusetts.Journal of urban health : bulletin of the New York Academy of Medicine · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Angela R BazziHerbert Wertheim School of Public Health, University of California, 9500 Gilman Drive, San Diego, La Jolla, 92093, CA, USA. abazzi@health.ucsd.edu.
Michelle BordeuFenway Health, Boston, MA, USA.
Katrina BaumgartnerGreater Lawrence Family Health Center, Lawrence, MA, USA.
Darien M SproesserFenway Health, Boston, MA, USA.
Christopher M BositisGreater Lawrence Family Health Center, Lawrence, MA, USA.
Douglas S KrakowerFenway Health, Boston, MA, USA.
Matthew J MimiagaFenway Health, Boston, MA, USA.
Katie B BielloFenway Health, Boston, MA, USA. katie_biello@brown.edu.
Fenway Health · USGreater Lawrence Family Health Center · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Efficacy of a community-based PrEP uptake intervention for people who inject drugs in the US NortheastR01DA051849 · NIDA · BROWN UNIVERSITY · PI BAZZI, ANGELA ROBERTSON, BIELLO, KATIE BROOKS · 2020 to 2024
$3.7M
Preventing HIV infection among people who inject drugs during COVID-19K01DA043412 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAZZI, ANGELA ROBERTSON · 2017 to 2021
$934k
NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI060354NIDA NIH HHS K01 DA043412NIDA NIH HHS R01 DA051849
6 · The paper itself

Abstract

backgroundHIV incidence has recently increased among people who inject drugs (PWID) across the United States, with outbreaks occurring in states with long-standing syringe service programs (SSPs) including Massachusetts (MA). Antiretroviral pre-exposure prophylaxis (PrEP) is an evidence-based HIV prevention strategy recommended for PWID, but uptake in this marginalized population is extraordinarily low.

methodsWe describe the design and procedures for a National Institute on Drug Abuse (NIDA)-funded (R01) randomized controlled trial (RCT) testing the efficacy of "PrEP for Health," a multicomponent behavioral intervention to increase PrEP uptake, adherence, and persistence among HIV-negative PWID attending SSPs in two areas of the U.S. Northeast that are heavily affected by injection-related HIV transmission. Participants are equally randomized to receive the "PrEP for Health" intervention (involving individually tailored HIV and PrEP education, motivational interviewing, problem-solving skills and planning, and ongoing navigation support) or an enhanced standard of care (eSOC) control condition involving a brief educational video on the utility of PrEP for HIV prevention. Co-primary outcomes are PrEP uptake (using medical/pharmacy records) and adherence (using tenofovir quantification in hair samples); a secondary outcome is PrEP persistence (using medical/pharmacy records) over 12 months. Major assessments occur at baseline, 1-, 3-, 6-, and 12-month follow-up visits. Planned analyses will examine intervention efficacy, specific hypothesized conceptual mediators of the intervention effect (e.g., self-perceived HIV risk; PrEP knowledge, interest in use, motivation, and behavioral skills) and epidemiologically linked moderators (e.g., age; gender; condomless vaginal or anal sex). DISCUSSION: Findings from our extensive preliminary research with the study population revealed that a multicomponent, theory-based intervention targeting PrEP knowledge, motivation, self-efficacy, behavioral skills, and structural barriers to PrEP access is urgently needed for PWID who are at risk of HIV acquisition. We also learned that SSPs represent a highly acceptable service setting for delivering such interventions. In this study, we are evaluating the efficacy of the "PrEP for Health" intervention. If efficacious, findings from our implementation evaluation could help guide its dissemination to diverse SSPs and possibly other community-based settings accessed by this population.

trial registrationClinicalTrials.gov number NCT04430257, registered June 12, 2020.

Indexed as

Anti-HIV AgentsDrug UsersHIV InfectionsPre-Exposure ProphylaxisSubstance Abuse, IntravenousAnti-Retroviral AgentsFemaleHumansRandomized Controlled Trials as TopicSexual BehaviorUnited StatesAnti-HIV AgentsAnti-Retroviral AgentsHIV infectionsMotivational interviewingNeedle-Exchange ProgramsOpioid-related DisordersPatient NavigationPre-Exposure ProphylaxisSelf EfficacySocial Cognitive TheorySubstance-related DisordersSubstance Use, Intravenous

Identifiers

PMID36932369
PMCPMC10021034
OpenAlexW4327739346

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read8
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.